Library

feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Electronic Resource
    Electronic Resource
    Springer
    Journal of molecular medicine 60 (1982), S. 521-525 
    ISSN: 1432-1440
    Keywords: Propranolol ; Pharmacokinetics ; Inotropy ; Propranolol ; Pharmakokinetik ; Inotropie
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Description / Table of Contents: Zusammenfassung Sechs gesunde Probanden erhielten in randomisierter Reihenfolge 20 mg Propranolol i.v. und 80 mg oral. Die Serumkonzentrationen an Propranolol wurden gaschromatographische über 24 h nach jeder Dosis bestimmt. Die kinetischen Variablen für Propranolol (±SE) lauten: Eliminationshalbwertzeit (t1/2β):5,3 h±0,6 h; Verteilungsvolumen: 2,3±0,3 l/kg; totale Clearance 4,9±0,3 ml/min/kg; berechnete Extraktionsrate: 0,23±0,02. Nach oraler Propranololgabe war t1/2β mit 3,8±0,2 h kürzer als nach i.v. Applikation und die systemische Verfügbarkeit mit 0,60±0,07 geringfügig niedriger als von der Extraktionsrate zu erwarten. Die steady state Serumkonzentrationen unter Mehrfachgabe (80 mg alle 12 h) lagen mit 47±5 ng/ml niedriger als die nach den Ergebnissen der Einmaldosis berechneten Spiegel (61±5 ng/ml). Die echokardiographisch bestimmten linksventrikulären Funktionsparameter (Kontraktionsgeschwindigkeit der Hinterwand, enddiastolischer Durchmesser), die unter der einmaligen 80 mg Dosis bestimmt wurden, zeigten eine Beeinträchtigung der Ventrikelfunktion mit einem Maximum 3 h nach Propranolol-Applikation. Dieser Zeitpunkt korrelierte mit den maximalen Serumkonzentrationen (341 ng/ml).
    Notes: Summary Six healthy volunteers received single 20-mg intravenous (IV) and 80-mg oral doses of propranolol on two occasions in random sequence. Serum propranolol concentrations were determined by gas chromatography in multiple samples drawn during 24 h after each dose. Mean (±SE) kinetic variables for IV propranolol were: elimination half-life (t1/2β), 5.3 (±0.6) h; volume of distribution, 2.3 (±0.3) l/kg; total clearance, 4.9 (±0.3) ml/min/kg; predicted extraction ratio, 0.23 (±0.02). After single oral doses, t1/2β (3.8±0.2 h) tended to be smaller than after the IV dose, and actual systemic availability (0.60±0.07) was less than that based on the predicted extraction ratio. During multiple oral dosage (80 mg every 12 h), observed steady state serum levels (47±5 ng/ml) tended to be less than those predicted based on the single oral dose (61±5 ng/ml), thus providing no evidence for reduced propranolol clearance at steady-state. Echocardiographic measurements of left ventricular performance (posterior wall velocity, diastolic dimensions) made during the single-dose oral study indicated significant impairment of function; impairment was maximal at 3 h post-dosage, and corresponded to the time of the peak serum propranolol concentration (341 ng/ml).
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 2
    ISSN: 1432-1440
    Keywords: Clorazepate dipotassium ; Desmethyldiazepam ; Pharmacokinetics ; Bioavailability ; Intramuscular injection ; Dikalium-Clorazepat ; Desmethyldiazepam ; Pharmakokinetik ; Bioverfügbarkeit ; intramuskuläre Injektion
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Description / Table of Contents: Zusammenfassung Bei 17 gesunden Versuchspersonen im Alter von 21–66 Jahren wurden Pharmakokinetik und biologische Verfügbarkeit von Desmethyldiazepam (DMDZ) nach Gabe von Dikalium-Clorazepat (DCP) bestimmt. Die kinetischen Variablen für DMDZ nach Gabe einer einmaligen intravenösen 20 mg Dosis von DCP lauten: Verteilungsvolumen 1,24 l/kg; Eliminationshalbwertzeit 65 h; totale Clearance 0,24 ml/min/kg Körpergewicht. Bei den männlichen Versuchspersonen ließ sich eine Tendenz der Zunahme der DMDZ-Halbwertzeiten mit höherem Alter erkennen; eine entsprechende Altersabhängigkeit traf für die weiblichen Versuchspersonen nicht zu. Nach oraler Gabe von 20 mg DCP ließ sich DMDZ rasch im Blut nachweisen; der mittlere maximale Plasmaspiegel von 356 ng/ml wurde 0,9 h nach Applikation gemessen. Im Vergleich zur intravenösen Injektion ergab sich für DMDZ eine systemische Bioverfügbarkeit von 100%. 10 der Versuchspersonen erhielten außerdem eine einmalige intramuskuläre Gabe von 20 mg DCP. Die mittleren maximalen DMDZ-Spiegel lagen bei 290 ng/ml, gemessen im Mittel 2,7 h nach der Injektion. Auch nach intramuskulärer Gabe war die biologische Verfügbarkeit von DMDZ vollständig. Bemerkenswert war die von der Applikationsart unabhängige Beständigkeit der individuellen Halbwertzeiten.
    Notes: Summary The pharmacokinetics and bioavailability of desmethyldiazepam (DMDZ), formed from its precursor clorazepate (CZP) dipotassium, were assessed in a series of 17 healthy volunteers aged 21–66 years. After a single 20-mg intravenous dose of CZP, mean kinetic variables for DMDZ were: volume of distribution, 1.24 l/kg; elimination half-life, 65 h; total clearance, 0.24 ml/min/kg. Among males, DMDZ half-life tended to be prolonged and clearance reduced with age, but this was not true for females. After oral administration of 20 mg CZP, appearance of DMDZ in the circulation was rapid; the mean peak plasma level was 356 ng/ml, reached an average of 0.9 h after dosage. Based on comparison with IV dosage, systemic availability of DMDZ was complete (100% absorption). Ten of the subjects also received a single 20-mg intramuscular dose of CZP. Mean peak DMDZ levels were 290 ng/ml, reaching an average of 2.7 h after dosage. Systemic availability of DMDZ was complete. Elimination half-life of DMDZ for a given individual was highly replicable from trial to trial regardless of the route of CZP administration.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 3
    Electronic Resource
    Electronic Resource
    Springer
    European journal of clinical pharmacology 12 (1977), S. 167-170 
    ISSN: 1432-1041
    Keywords: Practolol ; propranolol ; beta-adrenergic blocking drugs ; drug surveillance ; adverse drug reactions
    Source: Springer Online Journal Archives 1860-2000
    Topics: Chemistry and Pharmacology , Medicine
    Notes: Summary Adverse reactions to practolol were studied in 198 prospectively monitored hospitalized medical patients. The mean age of the practolol recipients was 57 years; angina and cardiac arrhythmias were the most common indications for therapy. Adverse reactions were attributed to practolol in 20 patients (10%). Fifteen of these twenty reactions involved impairment of cardiac function (bradyarrhythmias, heart block, congestive heart failure, hypotension), and in three instances the reaction was considered life-threatening. Three additional patients had cutaneous reactions attributed to the drug. Adverse reactions to practolol were not dose-related, but toxicity appeared to be more frequent among patients concurrently receiving quinidine. The frequency of cardiovascular complications of propranolol in a similar series of patients was nearly identical. However, no skin reactions were attributed to propranolol. The findings suggest that practolol and propranolol produce unwanted cardiovascular effects with nearly equal frequency among hospitalized patients. Cutaneous reactions to practolol are evident even during short-term use.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 4
    Electronic Resource
    Electronic Resource
    Oxford, UK : Blackwell Publishing Ltd
    Psychophysiology 3 (1967), S. 0 
    ISSN: 1469-8986
    Source: Blackwell Publishing Journal Backfiles 1879-2005
    Topics: Medicine , Psychology
    Notes: A series of experiments was conducted to determine whether any physiological changes accompany the previously observed drop in impedance of the electrodeskin circuit during the administration of electric shock. Two concentric shock electrodes were modified by the addition of devices to measure the local temperature, blood volume, and blood pulse volume changes occurring directly under the electrode. Subjects were given a series of shocks through one of these electrodes, but not the other, while the physiological measures were recorded at both sites.No significant differences in temperature and blood volume measures occurred between shocked and unshocked electrodes. However, directly correlated with the drastic drop in impedance of the shocked circuit was a marked increase in blood pulse volume, inferred to be a manifestation of the axon reflex. The two related effects were shown to be highly localized at or near the shocked electrode, and also to be characteristic only of the passage of current through electrode-skin junctions.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 5
    ISSN: 1471-4159
    Source: Blackwell Publishing Journal Backfiles 1879-2005
    Topics: Medicine
    Notes: Abstract: Triazolobenzodiazepines are in clinical use as hypnotics and anxiolytics. We analyzed in vivo receptor binding and brain concentrations of alprazolam, triazolam, and estazolam. Drug concentrations measured in the cerebral cortex 1 h after administration were directly proportional to dose for all three compounds. In vivo receptor binding, as defined by the specific uptake of [3H]Ro 15–1788, decreased with increasing doses of estazolam and triazolam, a finding indicating dose-related increases in receptor occupancy due to these compounds. Triazolam was substantially more potent, with an IC50 value of 16 ng/g, compared with 117 ng/g for estazolam. At higher doses of alprazolam (〉0.2 mg/kg), receptor binding by [3H]Ro 15–1788 likewise decreased with increasing dose of the former drug. However, at lower doses of alprazolam (0.02–0.05 mg/kg), which resulted in cortex concentrations of 2–7 ng/g, receptor binding was increased above control values in cortex, hypothalamus, and hippocampus but not in several other brain regions. Binding returned to control values at doses of ≤0.01 mg/kg. Similar results were obtained in time course studies. At 8 and 10 h after a dose of 1 mg/kg i.p., corresponding to cortex concentrations of 2.7–7 ng/g, receptor binding was increased compared with controls. Similarly, at 1, 2, and 3 h after a single dose of 0.05 mg/kg, corresponding to cortex concentrations of 3.7–5.8 ng/g, receptor binding was also increased. The apparent affinity of benzodiazepine receptors for clonazepam in mice receiving alprazolam (0.05 mg/kg) was unchanged from that in untreated control mice, an observation suggesting that low doses of alprazolam increased receptor number. The brain concentration vs. receptor occupancy relationships for triazolam and estazolam resemble those for other benzodiaze-pines, but alprazolam appears to be anomalous in that low brain concentrations increase benzodiazepine receptor number.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 6
    ISSN: 1471-4159
    Source: Blackwell Publishing Journal Backfiles 1879-2005
    Topics: Medicine
    Notes: Abstract: The irreversible protein-modifying reagent N-ethoxycarbonyl-2-ethoxy-1,2-dihydroquinoline (EEDQ) was used to investigate binding site characteristics on the γ-aminobutyric acidA (GABAA) receptor complex. In vitro, preincubation with EEDQ led to a concentration-dependent decrease in receptor number for benzodiazepine, t-butylbicyclophosphorothionate (TBPS), and GABA binding sites in cerebral cortex. The effect was maximal at the highest concentration of EEDQ used (10−4M) and was greatest for the benzodiazepine site. Pretreatment of membranes with the benzodiazepine antagonist Ro 15-1788, 1 or 10 μM, or the agonist lorazepam, 10 μM, largely prevented the effects of EEDQ. Scatchard analysis indicated no effect of EEDQ, 10−4M, on apparent affinity, but a decrease in receptor density for each site. Administration of EEDQ to mice, 12.5 mg/kg i.p., led to a substantial (55-65%) decrease in number of benzodiazepine binding sites in cortex after 4 h. Slightly smaller changes were observed for TBPS and GABA binding. No changes were observed in apparent affinity at any site. Prior administration of Ro 15-1788, 5 mg/kg, prevented the effect of EEDQ on benzodiazepine binding. Density of benzodiazepine binding sites gradually recovered over time, and receptor density returned to control values by 96 h after EEDQ injection. Number of binding sites in cortex for TBPS and GABA also increased over time after EEDQ. Benzodiazepine sites in cerebellum were decreased proportionally to cortex after EEDQ, and increased over a similar time course. Function of the GABAA receptor in chloride uptake in cortex was markedly reduced (65%) by EEDQ. Administration of EEDQ to senescent mice (20 months) led to a similar decrease in benzodiazepine sites compared to young mice, but receptor density returned more slowly to control levels (calculated receptor t1/2: young, 25.3 h; senescent, 75.1 h). EEDQ modifies all three major sites on the GABAA receptor, with the greatest effect at the benzodiazepine site. This compound may be useful in assessing benzodiazepine receptor half-life in vivo.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 7
    ISSN: 1360-0443
    Source: Blackwell Publishing Journal Backfiles 1879-2005
    Topics: Medicine , Psychology
    Notes: Aims  In the current study, nefazodone, an antidepressant with dual action on serotonin and norepinephrine reuptake as well as 5-HT2A receptor antagonist effects, was studied in subjects with cocaine dependence and depressive symptoms, to determine its efficacy in reducing cocaine use.Design  An 8-week, double blind, placebo-controlled design was used.Setting  The study was conducted at the Medication Development Research Unit (MDRU) at the VA Boston Healthcare System and the Manhattan Department of Veterans Affairs (DVA) Medical Center.Participants  Subjects (n = 69) met Diagnostic and Statistical Manual version IV (DSM-IV) criteria for cocaine dependence and had Hamilton Depression Scores of 12 or higher.Intervention  Subjects were assigned randomly to receive nefazodone 200 mg twice daily (n = 34) or matching placebo (n = 35). All subjects received individual counseling.Measurements  Urinary measurements of benzoylecgonine (BE, three times per week) and self-reports of cocaine use were the primary outcome measures. Secondary outcome measures included assessments of psychiatric functioning, cocaine craving and social functioning.Findings  Median weekly BE declined more rapidly in the nefazodone than in the placebo group. Median urine BE at baseline was, however, significantly greater in nefazodone than in the placebo group. Scores for strength of cocaine craving also decreased more rapidly in the nefazodone group compared to the placebo group. Both groups had equivalent improvement in mood, psychosocial functioning and self-reported cocaine use.Conclusions  These results suggest that nefazodone administration can reduce cocaine craving after it has been administered for several weeks. Although the nefazodone group had a greater rate of decrease in BE levels than the placebo group, the interpretation of this finding is obscured by significant group differences in baseline BE levels.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 8
    ISSN: 1432-2072
    Keywords: Flurazepam ; Benzodiazepines ; Receptors ; Pharmacokinetics ; Brain uptake
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract The benzodiazepine derivative flurazepam (FLZ) is widely used as a hypnotic, but the relative contributions of FLZ and its metabolites desalkylflurazepam (DA-FLZ), hydroxyethylflurazepam (ETOH-FLZ), and flurazepam aldehyde (CHO-FLZ) to overall clinical activity remain uncertain. A single 20 mg/kg dose of FLZ·HCl was administered to mice, with plasma and brain concentrations of FLZ and metabolites determined during 5 h after dosage. Brain and plasma concentrations of FLZ were maximal at 0.5 h after dosage, then declined rapidly in parallel, whereas those of DAFLZ were maximal at 2 h, then declined slowly. Concentrations of ETOH-FLZ, the most polar metabolite, were maximal at 0.5 h, and were undetectable after 3 h. Little CHO-FLZ was detected in either brain or plasma. A single 30-mg oral dose of FLZ·HCl was given to 18 human volunteers, with plasma levels determined over 9 days. FLZ was detected in plasma at low concentrations for no more than 3 h after dosage. ETOH-FLZ concentrations were higher and persisted for 8 h after dosage. CHO-FLZ reached intermediate peak levels and was present longer than FLZ or ETOH-FLZ. In contrast, DA-FLZ achieved the greatest peak concentrations, occurring at 10 h after dosage. Levels declined very slowly, with a mean half-life of 71.4 h, and were still detectable 9 days after FLZ dosage. Plasma free fractions (percent unbound) in mice were 40.3, 51.4, and 25.0% for FLZ, ETOH-FLZ and DA-FLZ, respectively; in humans, values were 17.2, 35.2, and 3.5%, respectively. Brain:free plasma ratios in mice for the three compounds were 8.17, 2.21 and 7.01, and were correlated with HPLC retention times, an index of lipophilicity (r=0.90), suggesting passive distribution from plasma to brain. In vitro specific binding affinities (K i) in rat brain membranes for FLZ, ETOH-FLZ, DA-FLZ, and CHO-FLZ were 12.7, 16.2, 0.85, and 10.6 nM, respectively. Thus after a single 20 mg/kg dose of FLZ in mice, DA-FLZ brain concentrations greatly exceeded its K i, while FLZ and ETOH-FLZ levels relative to their own K i values are one or more orders of magnitude lower. Since brain:free plasma ratios and binding characteristics for benzodiazepines appear similar in rodents and humans, similar conclusions can be drawn for humans based on pharmacokinetic and protein binding data. Pharmacodynamic effects after a single dose of FLZ in mice and humans are largely attributable to DA-FLZ, consistent with behavioral studies comparing relative potencies of metabolites.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 9
    ISSN: 1432-2072
    Keywords: Saccadic eye movements ; Smooth pursuit eye movements ; Diphenhydramine ; Diazepam ; Sedation ; Short-term memory
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract Peak saccadic eye movement velocity (SEV) and average smooth pursuit gain (SP) are reduced in a dose-dependent manner by diazepam and provide reliable, quantitative measures of benzodiazepine agonist effects. To evaluate the specificity of these eye movement effects for agents acting at the central GABA-benzodiazepine receptor complex and the role of sedation in benzodiazepine effects, we studied eye movement effects of diphenhydramine, a sedating drug which does not act at the GABA-benzodiazepine receptor complex. Ten healthy males, aged 19–28 years, with no history of axis I psychiatric disorders or substance abuse, received 50 mg/70 kg intravenous diphenhydramine or a similar volume of saline on separate days 1 week apart. SEV, saccade latency and accuracy, SP, self-rated sedation, and short-term memory were assessed at baseline and at 5, 15, 30, 45, 60, 90 and 120 min after drug administration. Compared with placebo, diphenhydramine produced significant SEV slowing, and increases in saccade latency and self-rated sedation. There was no significant effect of diphenhydramine on smooth pursuit gain, saccade accuracy, or short-term memory. These results suggest that, like diazepam, diphenhydramine causes sedation, SEV slowing, and an increase in saccade latency. Since the degree of diphenhydramine-induced sedation was not correlated with changes in SEV or saccade latency, slowing of saccadic eye movements is unlikely to be attributable to sedation alone. Unlike diazepam, diphenhydramine does not impair smooth pursuit gain, saccadic accuracy, or memory. Different neurotransmitter systems may influence the neural pathways involved in SEV and smooth pursuit gain.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 10
    ISSN: 1432-2072
    Keywords: Morphine ; Naltrexone ; GABA ; Benzodiazepine ; Chloride
    Source: Springer Online Journal Archives 1860-2000
    Topics: Medicine
    Notes: Abstract Behavioral and neurochemical evidence indicates links between the opioid and GABA neurotransmitter systems. To assess effects of chronic opiates on the major site of postsynaptic GABAergic activity, the GABAA receptor, we administered chronic morphine and naltrexone to mice and evaluated binding at the benzodiazepine andt-butylbicyclophosphorothionate (TBPS) sites and GABA-dependent chloride uptake. After morphine (3 days), benzodiazepine receptor binding in vivo but not in vitro was increased in cortex compared to placebo-treated mice. TBPS binding was unchanged in cortex, but muscimol-stimulated chloride uptake was increased at low doses of muscimol. Benzodiazepine and TBPS binding and muscimol-stimulated chloride uptake were unchanged in naltrexone-(8 days) compared to placebo-treated mice. When naltrexone was administered previously to block opiate sites, the increases in benzodiazepine binding and chloride uptake observed with chronic morphine were reversed. These results indicate that chronic morphine but not naltrexone enhances benzodiazepine binding and GABAA receptor function, perhaps by an action at opioid receptors.
    Type of Medium: Electronic Resource
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...